Walvax Biotechnology Co Ltd
SZSE:300142
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
9.9
24.78
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Walvax Biotechnology Co Ltd
Inventory
Walvax Biotechnology Co Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
W
|
Walvax Biotechnology Co Ltd
SZSE:300142
|
Inventory
ÂĄ1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
30%
|
CAGR 10-Years
10%
|
|
Beigene Ltd
HKEX:6160
|
Inventory
ÂĄ3B
|
CAGR 3-Years
72%
|
CAGR 5-Years
92%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Inventory
ÂĄ341.8m
|
CAGR 3-Years
77%
|
CAGR 5-Years
82%
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Inventory
ÂĄ905.5m
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Inventory
ÂĄ3.7B
|
CAGR 3-Years
13%
|
CAGR 5-Years
16%
|
CAGR 10-Years
25%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Inventory
ÂĄ15.7B
|
CAGR 3-Years
33%
|
CAGR 5-Years
43%
|
CAGR 10-Years
57%
|
Walvax Biotechnology Co Ltd
Glance View
Walvax Biotechnology Co., Ltd. engages in the research and development, production, and sale of biopharmaceutical products. The company is headquartered in Kunming, Yunnan and currently employs 1,866 full-time employees. The company went IPO on 2010-11-12. The Company’s main products include haemophilus influenza type b conjugate vaccines, freeze-dried group A,C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines and group A and C meningococcal polysaccharide vaccines, among others. The firm distributes its products mainly in domestic market.
See Also
What is Walvax Biotechnology Co Ltd's Inventory?
Inventory
1B
CNY
Based on the financial report for Jun 30, 2024, Walvax Biotechnology Co Ltd's Inventory amounts to 1B CNY.
What is Walvax Biotechnology Co Ltd's Inventory growth rate?
Inventory CAGR 10Y
10%
Over the last year, the Inventory growth was -12%. The average annual Inventory growth rates for Walvax Biotechnology Co Ltd have been 17% over the past three years , 30% over the past five years , and 10% over the past ten years .